688580 Nanjing Vishee Medical Technology Co., Ltd
- 45.89
- +0.25+0.55%
Nanjing Vishee Medical Technology Co., Ltd News
Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)
Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being co
Weiss Healthcare (688580): Steady growth in core business is expected to open up a second curve in medicine and aesthetics
Event: The company released its annual report for 2023 and the first quarter report for 2024. The company achieved operating income of 462 million yuan (+43.72%) and net profit of 136 million yuan (+4) for the full year of 2023
Express News | 32 companies disclose buyback progress
Weiss Healthcare (688580) 2023 Annual Report and 2024 Quarterly Report Review: The growth rate for the full year of 23 is impressive, and 24Q1 is under pressure in the short term
Performance summary: The company achieved revenue of 462 million yuan/ +43.72% in 2023, net profit of 136 million yuan/ +45.22%, after deducting net profit of 122 million yuan/ +58.93%. 202
Weiss Healthcare (688580): Quarterly Fluctuations Expect Medical and Aesthetic Volume
Key investment performance: On April 25, 2024, the company released its 2023 and 2024 quarterly reports. Specifically: 2023, revenue of 462 million yuan, YOY 43.72%, net return to mother
Weiss Healthcare (688580): Performance is in line with expectations, and the product matrix continues to be rich, driven by innovation, R&D
2023 and 1Q24 results are in line with market expectations The company announced 2023 results: revenue of $462 million (+43.72% YoY), net profit to mother of $136 million (+45.22% YoY)
Express News | Weiss Healthcare: Net profit for the first quarter of 2024 decreased by 27.69% year-on-year
Weiss Healthcare (688580.SH): A total cost of 13.107 million yuan to buy back 0.3467% of the shares
Gelonghui, April 1 | Weisi Healthcare (688580.SH) announced that as of March 31, 2024, the company had repurchased a total of 237,893 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange, accounting for 0.3467% of the company's total share capital. The highest price of the repurchase transaction was 65.88 yuan/share, the lowest price was 41.23 yuan/share, and the total amount of capital paid was RMB 13,107,011.20 (excluding transaction fees such as stamp duty and transaction fees).
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 22% over the past three months, it is easy to disregard Nanjing Vishee Medical Technology (SHSE:688580). But if you pay close attention, you might find that its key financial ind
Express News | Cinda Securities: Focus on investment opportunities brought about by medical equipment updates
Weiss Healthcare (688580.SH): No implantable neuromodulation products are currently being developed or sold
Gelonghui, March 11 | Weiss Healthcare (688580.SH) said on the investor interactive platform, according to the World Neuromodulation Society's definition of “neuroregulation” — that is, in the field of combining technology, medical treatment, and bioengineering technology, signals are transmitted to neurons or neural networks in the central, peripheral, and neighboring or remote parts of the autonomic nervous system through electrical or chemical effects, thereby improving patients' quality of life or improving body function. The company currently has long-term business in the field of non-implantable neuromodulation
Weiss Healthcare (688580.SH): Accumulated repurchases of 237,900 shares
Gelonghui, March 1, 丨 Weisi Healthcare (688580.SH) announced that as of February 29, 2024, the company had repurchased a total of 237,893 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange, accounting for 0.3467% of the company's total share capital. The highest price of the repurchase transaction was 65.88 yuan/share, the lowest price was 41.23 yuan/share, and the total amount of capital paid was RMB 13,107,011.20 (excluding transaction fees such as stamp duty and transaction fees).
Weiss Healthcare (688580) 2023 Earnings Report Review: Steady Growth in Q4 Performance, Innovation Drives Business Structure Optimization
Incident: The company released its 2023 performance report. It achieved operating income, net profit to mother, and net profit after deducting non-return to mother for the whole year of 4.62/1.36/ 122 million yuan, respectively, +43.72%/45.41% /58 compared to the same period last year
Weiss Healthcare (688580.SH) Performance Report: 2023 net profit of 136 million yuan, up 45.41% year on year
Gelonghui, Feb. 26 | Weiss Healthcare (688580.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 462 million yuan, up 43.72% year on year; net profit attributable to owners of the parent company was 136 million yuan, up 45.41% year on year. Net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 122 million yuan, up 58.90% year on year.
Weiss Healthcare (688580): Performance is close to forecast and demand for median rehabilitation products has recovered significantly
Incident: The company released the 2023 performance report. In 2023, the company expects to achieve operating income of 462 million yuan, an increase of 43.72% over the previous year, and achieve net profit of 136 million yuan to mother, an increase of 45.41% over the previous year.
Weiss Healthcare (688580.SH): Proven magnetic plastic products can meet the needs of body shaping and circumference reduction
Gelonghui, Feb. 19 | Weiss Healthcare (688580.SH) said on the investor interactive platform that the company is currently developing picosecond lasers with functions such as removing tattoos and treating skin pigment diseases, and are mainly used in dermatology, laser departments, medical aesthetic departments, medical aesthetic institutions, etc. The company's proven magnetic products can meet the needs of body shaping and circumference reduction, and can be used in pelvic floor centers, medical and aesthetic institutions, etc.
Weiss Healthcare (688580.SH) obtained a magnetic stimulator medical device registration certificate
Weiss Healthcare (688580.SH) issued an announcement. The company recently received an award from the Jiangsu Drug Administration...
Weiss Healthcare's high-tech products debut at Dubai Arab Health
Weiss Healthcare debuted at Arab Health in Dubai and showcased flagship products in the field of rehabilitation, such as pelvic floor magnetic MagBelle, plastic magnetic MagGraver, and transcranial magnetic MagNeuro. These products use non-invasive and painless magnetic stimulation technology to lead the industry and technical standards. Since its establishment in 2001, Weiss Medical has been deeply involved in the rehabilitation circuit, actively built a leading rehabilitation device product matrix, and is committed to scientific and technological innovation and strategic upgrading. (Medical news)
Weiss Healthcare brought a variety of products to Arab Health 2024 to expand the international market
DUBAI, Feb. 5, 2024/PRNewswire/ -- Recently, during the Arab Health exhibition in Dubai, Weiss Healthcare debuted with a high-tech flagship product, completing its international debut. Arab Health is the largest healthcare trade event in the Middle East. Known as the heart of healthcare in the Middle East, Arab Health brings together cutting-edge technology, revolutionary innovative concepts, and healthcare experts. About 200 countries, more than 3,000 exhibitors, and more than 100,000 people from around the world attended the event. Product image Weiss Healthcare is showcasing its flagship product in the field of rehabilitation: Pelvic Floor Magnetic MagBelle
Weiss Healthcare (688580.SH): A total cost of 9.977,800 yuan to buy back 0.2426% of the shares
Gelonghui, Feb. 1 | Weiss Healthcare (688580.SH) announced that as of January 31, 2024, the company had repurchased a total of 166,500 shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 0.2426% of the company's total share capital. The highest price of the repurchase transaction was 65.88 yuan/share, the lowest price was 48.47 yuan/share, and the total amount of capital paid was RMB 9,977,784.31.
Analysis
Price Target
No Data
